The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2024

Filed:

Oct. 16, 2020
Applicants:

The Regents of the University of California, Oakland, CA (US);

Atengen, Inc., Los Angeles, CA (US);

Inventors:

Hui Sun, Culver City, CA (US);

Pu Sun, San Jose, CA (US);

Guo Cheng, Los Angeles, CA (US);

Adrian Chichuen Au, Los Angeles, CA (US);

Ming Zhong, Nanjing, CN;

Assignees:

The Regents of the University of California, Oakland, CA (US);

Atengen, Inc., Los Angeles, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61P 35/00 (2006.01); C07D 215/42 (2006.01); C07D 215/44 (2006.01); C07D 215/46 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01); C07D 487/08 (2006.01); C07D 491/113 (2006.01); C07D 498/04 (2006.01); C07H 15/26 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61P 35/00 (2018.01); C07D 215/42 (2013.01); C07D 215/44 (2013.01); C07D 215/46 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 487/08 (2013.01); C07D 491/113 (2013.01); C07D 498/04 (2013.01); C07H 15/26 (2013.01);
Abstract

The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.


Find Patent Forward Citations

Loading…